HR 3546 · in committee · significant
Prescription Drug Price Relief Act of 2025
- healthcare
What this bill does
- HHS must review brand-name drug prices annually and void exclusivity if prices are found excessive.
- Drug manufacturers and patients affected by high-priced medications are impacted by this oversight.
- HHS creates a public database and expedites generic drug approvals; manufacturers must report financial data.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would HHS determine whether a brand-name drug's price is excessive, and what standards or benchmarks would guide that judgment?
- 02
What financial burden or timeline pressure might drug manufacturers face when required to report data and defend their pricing decisions?
- 03
Could accelerating generic drug approvals through this process reduce innovation incentives, or would market competition ultimately drive down prices for patients?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-CA-17
Ro Khanna
Citizen cosponsors
0
In Congress
4/ 435
House Reps cosponsoring
Introduced 2025-05-21
Joining the bill
Legislative timeline
2025-05-21 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-05-21 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-05-21 · IntroReferral
Introduced in House
2025-05-21 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.